Atripla

From Proteopedia
Revision as of 13:33, 8 October 2023 by Alexander Berchansky (talk | contribs) (New page: A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on Jul...)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigationJump to search

A fixed-dose triple combination of emtricitabine, tenofovir and efavirenz (Sustiva, marketed by Bristol-Myers Squibb) was approved by the U.S. Food and Drug Administration (FDA) on July 12, 2006, under the brand name Atripla.

Proteopedia Page Contributors and Editors (what is this?)

Alexander Berchansky

Retrieved from "https://proteopedia.org/index.php?title=Atripla&oldid=3899036"